Second, high pre‐treatment levels of ctDNA, and specifically of EGFR mutations in plasma prior to treatment with EGFR‐TKI, correlated with increased tumour burden and were associated with poor prognosis, echoing previous findings (Mok et al, 2015). The gene discussed is EGFR; the disease is neoplasm.